The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results